Analysts’ Viewpoint on Global Market for Cancer Diagnostics Scenario
Rise in cancer cases is expected to drive the global cancer diagnostics market in the next few years. This is ascribed to technological advancements, government initiatives, and funding. The development of companion diagnostics and the emergence of breakthrough detection technologies, such as proteomics, metabolomics, genomics, and transcriptomics, are likely to increase the demand for malignancy diagnostic devices. Cancer screening is critical to improve early detection and treatment of all cancers. Cancer awareness and early detection have increased in the last few decades, which resulted in subsequent reduction in mortality. However, the ultimate goal of reducing mortality from terminal cancer has not been fully achieved. Moreover, increased knowledge of specific cancer biomarkers enables the treatment of cancer patients through improved detection. Leading players in the market are engaged in the development of advanced diagnostic test for cancer.
Cancer is a complex and potentially fatal disease primarily caused by environmental factors that lead to genetic mutations affecting key cellular regulatory proteins. Extrinsic factors include tobacco, sun exposure, chemicals, alcohol, and infectious organisms. Internal factors include inherited genetic mutations, immune disorders, hormones, and random mutations. These factors may act together or in a sequence to induce tumorigenesis.
An increase in the incidence of cancer is expected to drive the demand for specific and effective cancer diagnostics. Early detection using state-of-the-art diagnostic techniques, such as immunoPET cancer diagnostics, immunohistochemistry, autoantibody, and intraoperative cancer diagnostics, enable rapid decision-making and consistent treatment. This prevents cancer from spreading until it becomes difficult to treat. Early antibody and cancer diagnostics, therefore, plays an important role in reducing treatment cost, shortening hospital stay, and avoiding inevitable procedures. Therefore, the growing trend of prophylactic diagnosis due to increasing prevalence leads to better clinical and economic outcomes for patients. This is expected to drive the global cancer diagnostics market size during the forecast period.
Non-invasive testing offers a relatively less expensive diagnosis, prognosis, and therapy selection. This aids oncologists in developing suitable treatment plans for cancer patients. The majority of individuals prefer non-invasive diagnostic procedures, as they are quicker and easier than invasive procedures since no tools are required to break the skin or enter the body.
Imaging tests, such as ultrasound, MRI, CT, mammography, and liquid biopsy, are non-invasive diagnostic tests for cancer detection. These tests are simpler and less expensive than blood, urine, or plasma tests. Hence, an increasing number of cancer patients are opting for painless imaging tests to diagnose and monitor cancer progression. This is likely to drive the demand for non-invasive cancer diagnostics tests during the forecast period.
The World Health Organization (WHO) estimates that cancer causes 8.3 million deaths annually, with a 70% increase in new cancer cases anticipated over the next 20 years. Different treatments are needed for different cancer types. Thus, the demand for liquid biopsy tests is projected to be high during the projected period owing to the increase in the incidence of cancer and the demand for individualized medications. The liquid biopsy procedure is still in the development stage. This is anticipated to present significant opportunities for market participants. Age-related risk accumulation for particular cancers is most likely the cause of a sharp rise in cancer incidence, which is attributed to increasing in the geriatric population. Moreover, aging people tend to have less efficient cellular repair systems.
In terms of test type, the global cancer diagnostics market has been segregated into tumor biomarker tests, imaging, endoscopy, and biopsy. The biopsy segment accounted for the largest market share in 2021 owing to continuous improvements in the procedure leading to the development of liquid biopsy gadgets. Additionally, a rise in awareness about non-invasive strategies; increased information about specific biomarkers such as lymphoma cancer diagnostics markers; higher cognizance; and equipment availability as the first line of cancer prognosis are driving the segment.
Based on application, the global cancer diagnostics market has been classified into breast cancer, blood cancer, pancreatic cancer, ovarian cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The lung cancer segment held the largest market share in 2021, as it is the leading cause of cancer in the U.S. and across the globe. Approximately, 85% of lung cancer is caused owing to smoking, and the rest 15% is due to changing lifestyles and other reasons. Smoking, a primary cause of small cell and non-small cell lung cancer, accounts for 80% and 90% of lung cancer deaths in women and men, respectively. Men who smoke are 23 times more likely to develop lung cancer.
In terms of end-user, the global cancer diagnostic market has been divided into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. The diagnostic laboratories segment accounted for the largest market share in 2021, as these laboratories are specifically designed to detect only tumor or mutated cells. People in developed countries prefer diagnostic laboratories, as they often use sophisticated equipment. This is expected to augment the segment.
North America is likely to dominate the global market during the forecast period due to changing demographics, evolving lifestyles, increasing prevalence of cancer, well-established point-of-care diagnostic centers, and availability of reimbursements.
Asia Pacific is expected to be a key market during the forecast period, as the prevalence of cancer is increasing in the region. Governments of countries, such as Japan, China, and India, fund and support universities and research institutes to develop new technologies for cancer diagnosis.
The cancer diagnostics market in Latin America is growing at a steady pace, as governments of several countries in the region are undertaking initiatives to provide basic health insurance and better treatment options for diseases such as cancer as the detection rate of early-stage cancers is quite low. This is ascribed to less awareness about the symptoms and the assumption that diagnostic tests could fail. Therefore, governments in Latin America are focusing on implementing early cancer detection strategies in order to obtain better treatment options.
A growing number of companies in Europe are engaging in strategic partnerships and acquisitions to strengthen their position in the cancer diagnostics business. This is expected to propel the market in the region during the forecast period.
The global cancer diagnostics market is fragmented, with the presence of a high number of large-sized players. Key players operating in the global cancer diagnostics business are Abbott, Agilent Technologies, Inc, Applied DNA Sciences, Becton, Dickinson and Company, bioMérieux SA, Eli Lilly and Company, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., General Electric Company, Hologic, Inc., Illumina, Inc., Menarini Silicon Biosystems, QIAGEN, Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc. These players are adopting strategies such as new product development, product launches, product approvals, agreements, partnerships, and mergers.
Each of these players has been profiled in the cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 163.7 Bn |
|
Market Forecast Value in 2031 |
More than US$ 335.7 Bn |
|
Growth Rate (CAGR) 2022-2031 |
7.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
.Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
The global market for cancer diagnostics was valued at US$ 163.7 Bn in 2021.
The global cancer diagnostics market is projected to reach more than US$ 335.7 Bn by 2031.
The global cancer diagnostics industry grew at a CAGR of 5.0% from 2017 to 2021.
The global market for cancer diagnostics is anticipated to grow at a CAGR of 7.4% from 2022 to 2031.
The biopsy segment held a major share of around 36% of the global market for cancer diagnostics in 2021.
North America is expected to account for a major share of the global cancer diagnostics market during the forecast period.
Abbott, Agilent Technologies, Inc., Applied DNA Sciences, Becton, Dickinson & Company, bioMérieux SA, Eli Lilly and Company, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., General Electric Company, Hologic, Inc., Illumina, Inc., Menarini Silicon Biosystems, QIAGEN, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Developments & New Approaches in Cancer Diagnosis
5.2. Cancer Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/Long-term Impact)
6. Global Cancer Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Tumor Biomarker Tests
6.3.1.1. Prostate Specific Antigen Tests
6.3.1.2. Circulating Tumor Cells (CTC) Tests
6.3.1.3. Alpha-fetoprotein (AFP) Tests
6.3.1.4. CA 19-9 Tests
6.3.1.5. CA 125 Tests
6.3.1.6. HER2
6.3.1.7. BRCA
6.3.1.8. KRAS
6.3.1.9. Others
6.3.2. Imaging
6.3.2.1. Magnetic Resonance Imaging (MRI) Scan
6.3.2.2. Positron Emission Tomography (PET) Scan
6.3.2.3. Computed Tomography (CT) Scan
6.3.2.4. Mammography
6.3.2.5. Others
6.3.3. Endoscopy
6.3.3.1. Colonoscopy
6.3.3.2. Bronchoscopy
6.3.3.3. Others
6.3.4. Biopsy
6.3.4.1. Bone Marrow Biopsy
6.3.4.2. Needle Biopsy
6.3.4.3. Endoscopic Biopsy
6.3.4.4. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global Cancer Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Lung Cancer
7.3.3. Colorectal Cancer
7.3.4. Prostate Cancer
7.3.5. Pancreatic Cancer
7.3.6. Blood Cancer
7.3.7. Ovarian Cancer
7.3.8. Melanoma
7.3.9. Other Cancers
7.4. Market Attractiveness Analysis, by Application
8. Global Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Diagnostic Laboratories
8.3.4. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Tumor Biomarker Tests
10.2.1.1. Prostate Specific Antigen Tests
10.2.1.2. Circulating Tumor Cells (CTC) Tests
10.2.1.3. Alpha-fetoprotein (AFP) Tests
10.2.1.4. CA 19-9 Tests
10.2.1.5. CA 125 Tests
10.2.1.6. HER2
10.2.1.7. BRCA
10.2.1.8. KRAS
10.2.1.9. Others
10.2.2. Imaging
10.2.2.1. Magnetic Resonance Imaging (MRI) Scan
10.2.2.2. Positron Emission Tomography (PET) Scan
10.2.2.3. Computed Tomography (CT) Scan
10.2.2.4. Mammography
10.2.2.5. Others
10.2.3. Endoscopy
10.2.3.1. Colonoscopy
10.2.3.2. Bronchoscopy
10.2.3.3. Others
10.2.4. Biopsy
10.2.4.1. Bone Marrow Biopsy
10.2.4.2. Needle Biopsy
10.2.4.3. Endoscopic Biopsy
10.2.4.4. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Breast Cancer
10.3.2. Lung Cancer
10.3.3. Colorectal Cancer
10.3.4. Prostate Cancer
10.3.5. Blood Cancer
10.3.6. Pancreatic Cancer
10.3.7. Ovarian Cancer
10.3.8. Melanoma
10.3.9. Other Cancers
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Diagnostic Laboratories
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Tumor Biomarker Tests
11.2.1.1. Prostate Specific Antigen Tests
11.2.1.2. Circulating Tumor Cells (CTC) Tests
11.2.1.3. Alpha-fetoprotein (AFP) Tests
11.2.1.4. CA 19-9 Tests
11.2.1.5. CA 125 Tests
11.2.1.6. HER2
11.2.1.7. BRCA
11.2.1.8. KRAS
11.2.1.9. Others
11.2.2. Imaging
11.2.2.1. Magnetic Resonance Imaging (MRI) Scan
11.2.2.2. Positron Emission Tomography (PET) Scan
11.2.2.3. Computed Tomography (CT) Scan
11.2.2.4. Mammography
11.2.2.5. Others
11.2.3. Endoscopy
11.2.3.1. Colonoscopy
11.2.3.2. Bronchoscopy
11.2.3.3. Others
11.2.4. Biopsy
11.2.4.1. Bone Marrow Biopsy
11.2.4.2. Needle Biopsy
11.2.4.3. Endoscopic Biopsy
11.2.4.4. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Breast Cancer
11.3.2. Lung Cancer
11.3.3. Colorectal Cancer
11.3.4. Prostate Cancer
11.3.5. Pancreatic Cancer
11.3.6. Ovarian Cancer
11.3.7. Blood Cancer
11.3.8. Melanoma
11.3.9. Other Cancers
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Diagnostic Laboratories
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Tumor Biomarker Tests
12.2.1.1. Prostate Specific Antigen Tests
12.2.1.2. Circulating Tumor Cells (CTC) Tests
12.2.1.3. Alpha-fetoprotein (AFP) Tests
12.2.1.4. CA 19-9 Tests
12.2.1.5. CA 125 Tests
12.2.1.6. HER2
12.2.1.7. BRCA
12.2.1.8. KRAS
12.2.1.9. Others
12.2.2. Imaging
12.2.2.1. Magnetic Resonance Imaging (MRI) Scan
12.2.2.2. Positron Emission Tomography (PET) Scan
12.2.2.3. Computed Tomography (CT) Scan
12.2.2.4. Mammography
12.2.2.5. Others
12.2.3. Endoscopy
12.2.3.1. Colonoscopy
12.2.3.2. Bronchoscopy
12.2.3.3. Others
12.2.4. Biopsy
12.2.4.1. Bone Marrow Biopsy
12.2.4.2. Needle Biopsy
12.2.4.3. Endoscopic Biopsy
12.2.4.4. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Breast Cancer
12.3.2. Lung Cancer
12.3.3. Colorectal Cancer
12.3.4. Prostate Cancer
12.3.5. Pancreatic Cancer
12.3.6. Ovarian Cancer
12.3.7. Blood Cancer
12.3.8. Melanoma
12.3.9. Other Cancers
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Diagnostic Laboratories
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Tumor Biomarker Tests
13.2.1.1. Prostate Specific Antigen Tests
13.2.1.2. Circulating Tumor Cells (CTC) Tests
13.2.1.3. Alpha-fetoprotein (AFP) Tests
13.2.1.4. CA 19-9 Tests
13.2.1.5. CA 125 Tests
13.2.1.6. HER2
13.2.1.7. BRCA
13.2.1.8. KRAS
13.2.1.9. Others
13.2.2. Imaging
13.2.2.1. Magnetic Resonance Imaging (MRI) Scan
13.2.2.2. Positron Emission Tomography (PET) Scan
13.2.2.3. Computed Tomography (CT) Scan
13.2.2.4. Mammography
13.2.2.5. Others
13.2.3. Endoscopy
13.2.3.1. Colonoscopy
13.2.3.2. Bronchoscopy
13.2.3.3. Others
13.2.4. Biopsy
13.2.4.1. Bone Marrow Biopsy
13.2.4.2. Needle Biopsy
13.2.4.3. Endoscopic Biopsy
13.2.4.4. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Breast Cancer
13.3.2. Lung Cancer
13.3.3. Colorectal Cancer
13.3.4. Prostate Cancer
13.3.5. Melanoma
13.3.6. Pancreatic Cancer
13.3.7. Blood Cancer
13.3.8. Ovarian Cancer
13.3.9. Other Cancers
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Diagnostic Laboratories
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Tumor Biomarker Tests
14.2.1.1. Prostate Specific Antigen Tests
14.2.1.2. Circulating Tumor Cells (CTC) Tests
14.2.1.3. Alpha-fetoprotein (AFP) Tests
14.2.1.4. CA 19-9 Tests
14.2.1.5. CA 125 Tests
14.2.1.6. HER2
14.2.1.7. BRCA
14.2.1.8. KRAS
14.2.1.9. Others
14.2.2. Imaging
14.2.2.1. Magnetic Resonance Imaging (MRI) Scan
14.2.2.2. Positron Emission Tomography (PET) Scan
14.2.2.3. Computed Tomography (CT) Scan
14.2.2.4. Mammography
14.2.2.5. Others
14.2.3. Endoscopy
14.2.3.1. Colonoscopy
14.2.3.2. Bronchoscopy
14.2.3.3. Others
14.2.4. Biopsy
14.2.4.1. Bone Marrow Biopsy
14.2.4.2. Needle Biopsy
14.2.4.3. Endoscopic Biopsy
14.2.4.4. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Breast Cancer
14.3.2. Lung Cancer
14.3.3. Colorectal Cancer
14.3.4. Prostate Cancer
14.3.5. Pancreatic Cancer
14.3.6. Ovarian Cancer
14.3.7. Blood Cancer
14.3.8. Melanoma
14.3.9. Other Cancers
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers
14.4.3. Diagnostic Laboratories
14.4.4. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Agilent Technologies, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Applied DNA Sciences
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Becton, Dickinson and Company
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. bioMérieux SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eli Lilly and Company
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Exact Sciences Corporation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. F. Hoffmann-La Roche Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. General Electric Company
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Hologic, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Illumina, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Menarini Silicon Biosystems
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. QIAGEN
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Siemens Healthcare GmbH
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. Thermo Fisher Scientific, Inc.
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview
List of Tables
Table 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 02: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 07: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 11: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 15: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 19: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031
Table 23: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Cancer Diagnostics Market Value Share, by Test Type, 2021
Figure 03: Global Cancer Diagnostics Market Value Share, by Application, 2021
Figure 04: Global Cancer Diagnostics Market Value Share, by End-user 2021
Figure 05: Global Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
Figure 06: Global Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 07: Global Cancer Diagnostics Market Value (US$ Mn), by Tumor Biomarker Tests, 2017‒2031
Figure 08: Global Cancer Diagnostics Market Value (US$ Mn), by Prostate Specific Antigen Tests, 2017‒2031
Figure 09: Global Cancer Diagnostics Market Value (US$ Mn), by Circulating Tumor Cells (CTC) Tests, 2017‒2031
Figure 10: Global Cancer Diagnostics Market Value (US$ Mn), by Alpha-fetoprotein (AFP) Tests, 2017‒2031
Figure 11: Global Cancer Diagnostics Market Value (US$ Mn), by CA 19-9 Tests, 2017‒2031
Figure 12: Global Cancer Diagnostics Market Value (US$ Mn), by CA 125 Tests, 2017‒2031
Figure 13: Global Cancer Diagnostics Market Value (US$ Mn), by HER2, 2017‒2031
Figure 14: Global Cancer Diagnostics Market Value (US$ Mn), by BRCA, 2017‒2031
Figure 15: Global Cancer Diagnostics Market Value (US$ Mn), by KRAS, 2017‒2031
Figure 16: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017‒2031
Figure 17: Global Cancer Diagnostics Market Value (US$ Mn), by Imaging, 2017‒2031
Figure 18: Global Cancer Diagnostics Market Value (US$ Mn), by Magnetic Resonance Imaging (MRI) Scan, 2017‒2031
Figure 19: Global Cancer Diagnostics Market Value (US$ Mn), by Positron Emission Tomography (PET) Scan, 2017‒2031
Figure 20: Global Cancer Diagnostics Market Value (US$ Mn), by Computed Tomography (CT) Scan, 2017‒2031
Figure 21: Global Cancer Diagnostics Market Value (US$ Mn), by Mammography, 2017‒2031
Figure 22: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017‒2031
Figure 23: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopy, 2017‒2031
Figure 24: Global Cancer Diagnostics Market Value (US$ Mn), by Colonoscopy, 2017‒2031
Figure 25: Global Cancer Diagnostics Market Value (US$ Mn), by Bronchoscopy, 2017‒2031
Figure 26: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017‒2031
Figure 27: Global Cancer Diagnostics Market Value (US$ Mn), by Biopsy, 2017‒2031
Figure 28: Global Cancer Diagnostics Market Value (US$ Mn), by Bone Marrow Biopsy, 2017‒2031
Figure 29: Global Cancer Diagnostics Market Value (US$ Mn), by Needle Biopsy, 2017‒2031
Figure 30: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopic Biopsy, 2017‒2031
Figure 31: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017‒2031
Figure 32: Global Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 33: Global Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 34: Global Cancer Diagnostics Market Revenue (US$ Mn), by Breast Cancer, 2017–2031
Figure 35: Global Cancer Diagnostics Market Revenue (US$ Mn), by Lung Cancer, 2017–2031
Figure 36: Global Cancer Diagnostics Market Revenue (US$ Mn), by Colorectal Cancer, 2017–2031
Figure 37: Global Cancer Diagnostics Market Revenue (US$ Mn), by Prostate Cancer, 2017–2031
Figure 38: Global Cancer Diagnostics Market Revenue (US$ Mn), by Pancreatic Cancer, 2017–2031
Figure 39: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ovarian Cancer, 2017–2031
Figure 40: Global Cancer Diagnostics Market Revenue (US$ Mn), by Blood Cancer, 2017–2031
Figure 41: Global Cancer Diagnostics Market Revenue (US$ Mn), by Melanoma, 2017–2031
Figure 42: Global Cancer Diagnostics Market Revenue (US$ Mn), by Other Cancers, 2017–2031
Figure 43: Global Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 44: Global Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 45: Global Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals 2017–2031
Figure 46: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ambulatory Surgical Centers, 2017–2031
Figure 47: Global Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories, 2017–2031
Figure 48: Global Cancer Diagnostics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 49: Global Cancer Diagnostics Market Value Share Analysis, by Region, 2021 and 2031
Figure 50: Global Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022–2031
Figure 51: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 52: North America Cancer Diagnostics Market Value Share Analysis, by Country, 2021 and 2031
Figure 53: North America Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022–2031
Figure 54: North America Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
Figure 55: North America Cancer Diagnostics Market Attractiveness Analysis, by Test Type 2022–2031
Figure 56: North America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 57: North America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 58: North America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 59: North America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 60: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Europe Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 62: Europe Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 63: Europe Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
Figure 64: Europe Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 65: Europe Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 66: Europe Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 67: Europe Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 68: Europe Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 69: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 70: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 71: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 72: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
Figure 73: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 74: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 75: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 76: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 77: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 78: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 79: Latin America Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 80: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 81: Latin America Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
Figure 82: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 83: Latin America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 84: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 85: Latin America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 86: Latin America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 87: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 88: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 89: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 90: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
Figure 91: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 92: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
Figure 93: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022–2031
Figure 94: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 95: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 96: Company Share Analysis, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Diagnostics Market
